Journal

Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834

Informations de publication

Date de publication:
Historique:
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 19 8 2021
Statut: ppublish

Résumé

This study aimed to investigate the effect of

Identifiants

pubmed: 32456485
doi: 10.1177/1534735420923756
pmc: PMC7265736
doi:

Substances chimiques

Hedgehog Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1534735420923756

Références

Front Biosci (Landmark Ed). 2012 Jan 01;17:90-9
pubmed: 22201734
Cell Physiol Biochem. 2018;50(1):398-409
pubmed: 30286481
Life Sci. 2004 Dec 10;76(4):385-95
pubmed: 15530501
Nat Rev Cancer. 2011 May 26;11(7):493-501
pubmed: 21614026
Cancers (Basel). 2016 Feb 15;8(2):
pubmed: 26891329
Cancer Chemother Pharmacol. 2008 Feb;61(2):251-65
pubmed: 17487491
Dev Biol. 2017 Oct 1;430(1):156-165
pubmed: 28800946
Science. 1998 Dec 18;282(5397):2244-6
pubmed: 9856944
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Int J Mol Sci. 2018 Sep 19;19(9):
pubmed: 30235830
Int J Mol Med. 2014 Nov;34(5):1349-57
pubmed: 25176413
Anticancer Res. 2006 Jan-Feb;26(1A):43-7
pubmed: 16475677
J Pharm Pharmacol. 2013 Apr;65(4):474-93
pubmed: 23488776
Cell Death Discov. 2018 May 23;4:62
pubmed: 29844932
Molecules. 2015 Jul 31;20(8):13927-40
pubmed: 26263965
Biomed Res Int. 2016;2016:7969286
pubmed: 28105432
Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):347-53
pubmed: 18806893
J Agric Food Chem. 2012 May 16;60(19):4905-13
pubmed: 22512531
Evid Based Complement Alternat Med. 2017;2017:8474703
pubmed: 28761499
Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19
pubmed: 21701501
Oncotarget. 2017 Feb 14;8(7):12211-12224
pubmed: 28099944
J Ethnopharmacol. 2010 Sep 15;131(2):363-7
pubmed: 20633630
J Pharm Pharmacol. 2005 Dec;57(12):1509-19
pubmed: 16354395
Anticancer Res. 2007 Sep-Oct;27(5A):3143-6
pubmed: 17970055
Cell Death Dis. 2018 Jun 13;9(6):708
pubmed: 29899333
Oncotarget. 2016 May 3;7(18):26916-24
pubmed: 27029035
PLoS One. 2011 Jan 13;6(1):e16068
pubmed: 21249152
Ann Neurosci. 2014 Jan;21(1):28-31
pubmed: 25206052
Cancer Res. 2005 Oct 15;65(20):9455-62
pubmed: 16230409
Am J Hum Genet. 2012 Aug 10;91(2):372-8
pubmed: 22883145
Int J Mol Sci. 2018 Aug 29;19(9):
pubmed: 30158435
Int J Mol Sci. 2018 Aug 08;19(8):
pubmed: 30096798
PLoS One. 2013 May 07;8(5):e63226
pubmed: 23667589
Am J Transl Res. 2019 Nov 15;11(11):6890-6906
pubmed: 31814895
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Oncol Rep. 2005 Jun;13(6):1211-6
pubmed: 15870944
BMC Complement Med Ther. 2020 Jan 13;20(1):1
pubmed: 32020859
Cell Commun Signal. 2018 Mar 20;16(1):11
pubmed: 29558958
Br J Haematol. 2008 Mar;140(6):682-391
pubmed: 18205859
Neuro Oncol. 2001 Jul;3(3):152-8
pubmed: 11465395
Daru. 2015 Jul 04;23:35
pubmed: 26141646
Med Sci Monit. 2017 Jan 26;23:452-461
pubmed: 28123172
Evid Based Complement Alternat Med. 2015;2015:767136
pubmed: 26421052
Recent Pat Biotechnol. 2007;1(2):123-37
pubmed: 19075836
Am J Cancer Res. 2016 Aug 01;6(8):1758-71
pubmed: 27648363
Oncogene. 2007 Feb 15;26(7):1046-55
pubmed: 16909105
PLoS One. 2017 Oct 18;12(10):e0186489
pubmed: 29045468
J Hematol Oncol. 2013 Oct 07;6(1):77
pubmed: 24199791
Sci Rep. 2019 Apr 29;9(1):6620
pubmed: 31036836
Genes Dev. 2008 Sep 15;22(18):2454-72
pubmed: 18794343
3 Biotech. 2014 Feb;4(1):1-12
pubmed: 28324458
Cancer Cell. 2003 Sep;4(3):167-74
pubmed: 14522250
Eur Respir Rev. 2017 Nov 15;26(146):
pubmed: 29141962
Int J Mol Sci. 2019 Mar 16;20(6):
pubmed: 30884815
Am J Cancer Res. 2017 Mar 01;7(3):417-432
pubmed: 28401001
Methods Cell Biol. 2009;94:199-222
pubmed: 20362092
Cold Spring Harb Perspect Biol. 2017 May 1;9(5):
pubmed: 27881449
Pharmacol Res. 2019 Jun;144:79-89
pubmed: 30974169
Theranostics. 2018 Oct 22;8(19):5259-5275
pubmed: 30555545
Nutr Cancer. 2015;67(3):411-23
pubmed: 25649862
Biol Pharm Bull. 2006 Apr;29(4):670-4
pubmed: 16595897
Mol Cells. 2017 Apr;40(4):243-253
pubmed: 28401750
Biomol Ther (Seoul). 2016 Jul 1;24(4):402-9
pubmed: 27068261

Auteurs

Eunbi Jo (E)

Korea Basic Science Institute, Daejeon, Republic of Korea.
Hanyang University, Seoul, Republic of Korea.

Hyun-Jin Jang (HJ)

Korea Basic Science Institute, Daejeon, Republic of Korea.
Sungkyunkwan University, Suwon, Republic of Korea.

Lei Shen (L)

Wonkwang University, Iksan, Republic of Korea.

Kyeong Eun Yang (KE)

Korea Basic Science Institute, Daejeon, Republic of Korea.

Min Su Jang (MS)

Yonsei University, Wonju, Republic of Korea.

Yang Hoon Huh (YH)

Korea Basic Science Institute, Cheongju, Republic of Korea.

Hwa-Seung Yoo (HS)

Daejeon University, Daejeon, Korea.

Junsoo Park (J)

Yonsei University, Wonju, Republic of Korea.

Ik Soon Jang (IS)

Korea Basic Science Institute, Daejeon, Republic of Korea.
University of Science and Technology, Daejeon, Republic of Korea.

Soo Jung Park (SJ)

Woosuk University, Wanju, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH